[ad_1]
Remember that the United States administration provided federal funds for the development of this vaccine.
“By the end of the year, the company plans to introduce 20 million doses,” says The Guardian.
Another important factor is the final price of this vaccine.
“It just came to our notice then. In the summer, Moderna focused on $ 37 per dose, which is significantly more expensive than Johnson & Johnson ($ 10) or Pfizer ($ 20) vaccines, according to the publication.
He predicts that in the case of large purchases, Moderna will likely accept a price reduction.
“But in any case, it is a for-profit company, and he made it clear that he was going to run it,” writes The Guardian.
“Given the price of the vaccine and Moderna’s relationship with the US administration, the rest of the world will have to pay for it, and low-income countries will likely have to look for alternatives,” the authors emphasize.
Western media claim that the Modern COVID-19 vaccine has great advantages. For example, it is particularly suitable for people over 65 years of age and its side effects are short-lived and mild in nature. In particular, in some cases, the test participants experienced hand pain and fatigue after the injection.
Moderna said Monday that its experimental COVID-19 vaccine had shown 94.5 percent. effectiveness. Also, according to its developers, the vaccine can be stored for a month at 2-8 degrees at room temperature.
In comparison, Pfizer and BioNTech vaccines must be stored at a room temperature of minus 70-80 degrees, which greatly complicates their logistics, and the poorest countries simply will not have the necessary equipment.
[ad_2]
